Skip to content

Study · Randomized controlled trial · n = 32 · 2018

6 results

Effect of liraglutide on dietary lipid-induced insulin resistance in humans.

Koska J, Lopez L, D'Souza K, Osredkar T, Deer J, Kurtz J, Salbe AD, Harman SM, Reaven PD

Diabetes, obesity & metabolism10 Aug 2017Cited by 15 (Europe PMC)

PMID28605158 (opens in a new tab)DOI10.1111/dom.13037 (opens in a new tab)PepBankPUB-28605158
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with normal or mildly impaired glucose tolerance on a saturated fat diet, liraglutide reduced plasma glucose by 50% versus placebo.

    In plain wordsIn adults with normal or slightly impaired glucose tolerance, liraglutide lowered blood glucose by 50% compared with placebo on a high saturated fat diet.

    Peptide
    Liraglutide
    Outcome
    DecreasePlasma glucose during SFA diet
    Study

    n = 32

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 3 weeksAs given in this study (human).

    Measurements

    Plasma glucose reduction
    50%
    SFA diet

    Source sentences

    Summary
    Liraglutide reduced plasma glucose, triglycerides and NEFA concentrations during the SFA diet (by 50%, 25% and 9%, respectively)
    1 context sentence
    Summary · context
    In a randomized placebo-controlled crossover study, 32 participants with normal or mildly impaired glucose tolerance received liraglutide and placebo for 3 weeks each.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with normal or mildly impaired glucose tolerance on a saturated fat diet, liraglutide reduced plasma triglycerides by 25% versus placebo.

    In plain wordsIn adults with normal or slightly impaired glucose tolerance, liraglutide lowered blood triglycerides by 25% compared with placebo during a high saturated fat diet.

    Peptide
    Liraglutide
    Outcome
    DecreasePlasma triglycerides during SFA diet
    Study

    n = 32

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated · 3 weeksAs given in this study (human).

    Measurements

    Triglyceride reduction
    25%
    SFA diet

    Source sentences

    Summary
    Liraglutide reduced plasma glucose, triglycerides and NEFA concentrations during the SFA diet (by 50%, 25% and 9%, respectively)
    1 context sentence
    Summary · context
    In a randomized placebo-controlled crossover study, 32 participants with normal or mildly impaired glucose tolerance received liraglutide and placebo for 3 weeks each.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with normal or mildly impaired glucose tolerance on a saturated fat diet, liraglutide reduced plasma non-esterified fatty acids by 9% versus placebo.

    In plain wordsIn adults on a high saturated fat diet, liraglutide lowered blood free fatty acids by 9% compared with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreasePlasma NEFA during SFA diet
    Study

    n = 32

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated · 3 weeksAs given in this study (human).

    Measurements

    NEFA reduction
    9%
    SFA diet

    Source sentences

    Summary
    Liraglutide reduced plasma glucose, triglycerides and NEFA concentrations during the SFA diet (by 50%, 25% and 9%, respectively)
    1 context sentence
    Summary · context
    In a randomized placebo-controlled crossover study, 32 participants with normal or mildly impaired glucose tolerance received liraglutide and placebo for 3 weeks each.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults on a saturated fat diet, liraglutide ameliorated the diet-induced impairment of vasodilation seen on placebo (-4.8% versus -9.4% from baseline).

    In plain wordsIn adults on a high saturated fat diet, liraglutide reduced the loss of blood vessel widening seen on placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseInsulin-mediated vasodilation of adipose arterioles
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 3 weeksAs given in this study (human).

    Measurements

    Vasodilation change
    −4.8%
    liraglutide
    Vasodilation change
    −9.4%
    placebo

    Source sentences

    Summary
    The SFA diet-induced impairment of vasodilation on placebo (-9.4% vs baseline; P < .01) was ameliorated by liraglutide (-4.8%; P = .1 vs baseline).
    1 context sentence
    Summary · context
    In a randomized placebo-controlled crossover study, 32 participants with normal or mildly impaired glucose tolerance received liraglutide and placebo for 3 weeks each.
  5. 05HumanRandomized controlled trialMechanism

    In skeletal muscle of adults on a saturated fat diet, liraglutide abolished the diet-induced increase in TxNIP expression (75% decrease versus placebo).

    In plain wordsIn muscle of adults on a high saturated fat diet, liraglutide lowered TxNIP, a protein linked to insulin resistance, by 75% compared with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseSkeletal muscle TxNIP expression
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Receptor activity and mechanism · Metabolic and weight
    Studied dose
    Dose not stated · 3 weeksAs given in this study (human).

    Measurements

    TxNIP expression decrease
    75%
    skeletal muscle

    Source sentences

    Summary
    In skeletal muscle, liraglutide abolished the SFA-induced increase in thioredoxin-interacting protein (TxNIP) expression (75% decrease; P < .01 vs placebo)
    1 context sentence
    Summary · context
    In a randomized placebo-controlled crossover study, 32 participants with normal or mildly impaired glucose tolerance received liraglutide and placebo for 3 weeks each.
  6. 06HumanRandomized controlled trialMechanism

    In skeletal muscle of adults on a saturated fat diet, liraglutide increased AMPK phosphorylation by 50% versus -3% with placebo.

    In plain wordsIn muscle of adults on a high saturated fat diet, liraglutide raised AMPK activation by 50%, compared with a 3% fall on placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseSkeletal muscle AMPK phosphorylation
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Receptor activity and mechanism · Metabolic and weight
    Studied dose
    Dose not stated · 3 weeksAs given in this study (human).

    Measurements

    AMPK phosphorylation change
    50%
    liraglutide
    AMPK phosphorylation change
    −3%
    placebo

    Source sentences

    Summary
    and increased 5'AMP-activated protein kinase (AMPK) phosphorylation (50% vs -3%; P = .04 vs placebo).
    1 context sentence
    Summary · context
    In a randomized placebo-controlled crossover study, 32 participants with normal or mildly impaired glucose tolerance received liraglutide and placebo for 3 weeks each.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.